1. A therapeutic agent for amyotrophic lateral sclerosis containing a growth hormone secretion stimulating receptor agonist or a pharmaceutically acceptable salt thereof as an active ingredient for administration to an individual suffering from amyotrophic lateral sclerosis without severe dysphagia. The therapeutic agent of claim 1, wherein the individual is also immune or insufficiently susceptible to an existing therapeutic agent for amyotrophic lateral sclerosis. A therapeutic agent according to claim 1 or 2, wherein the therapeutic agent is used in combination with an existing therapeutic agent for amyotrophic lateral sclerosis. The therapeutic agent according to claim 2, wherein the existing therapeutic agent for amyotrophic lateral sclerosis is riluzole. A therapeutic agent according to claim 1 or 2, wherein the therapeutic agent for amyotrophic lateral sclerosis, comprising a growth hormone secretion stimulating receptor agonist or a pharmaceutically acceptable salt thereof as an active ingredient, is administered by subcutaneous injection. The therapeutic agent according to claim 1 or 2, wherein the growth hormone secretion stimulating receptor agonist is ghrelin, pralmorelin, GHRP-6, hexarelin, ipamorelin, ibamorena mesylate, ulmorelline, anamorelin, macemorelin, capromorelin or SM-130686. The therapeutic agent of claim 6, wherein the ghrelin is a peptide compound comprising the amino acid sequence of SEQ ID NO: 1, wherein the 3rd amino acid residue from the N-terminus is an amino acid residue modified with a fatty acid introduced into the side chain1. Терапевтическое средство для бокового амиотрофического склероза, содержащее агонист рецептора стимулятора секреции гормона роста или его фармацевтически приемлемую соль в качестве активного ингредиента, для введения индивидууму, страдающему боковым амиотрофическим склерозом без тяжелой дисфагии.2. Терапевтическое средство по п. 1, где индивидуум также является невосприимчивым или недостаточно восприимчивым к
